Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1981
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06AX05
|
| gptkbp:availableOn |
gptkb:tablet
|
| gptkbp:brand |
gptkb:trazodone
|
| gptkbp:chemicalClass |
triazolopyridine
|
| gptkbp:contraindication |
concurrent use with MAO inhibitors
hypersensitivity to trazodone |
| gptkbp:developedBy |
gptkb:Angelini
|
| gptkbp:eliminationHalfLife |
5-13 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Desyrel
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:mechanismOfAction |
serotonin antagonist and reuptake inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
nausea dizziness headache drowsiness dry mouth |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
insomnia |
| gptkbp:bfsParent |
gptkb:Trazodone
|
| gptkbp:bfsLayer |
7
|